USC-Norris Cancer Center

Phase	Trial	Trial Status [desc]	Site Status	Drug	NCT#
1/2	A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
1	A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Recruiting	Active	Ziftomenib + Imatinib	NCT06655246
2	Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	Ongoing, but not recruiting	Closed	Sorafenib (Nexavar, BAY 43-9006)	NCT00265798
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753